Results 231 to 240 of about 308,172 (351)
Genetic epilepsies with myoclonic seizures: Mechanisms and syndromes
Abstract Genetic epilepsy with myoclonic seizures encompasses a heterogeneous spectrum of conditions, ranging from benign and self‐limiting forms to severe, progressive disorders. While their causes are diverse, a significant proportion stems from genetic abnormalities.
Antonietta Coppola +3 more
wiley +1 more source
A 10-Year-Old Boy With Ataxia-Telangiectasia: A Rare Case Report From Yemen. [PDF]
Muneer M +8 more
europepmc +1 more source
Bilateral sensorineural hearing loss and cerebellar ataxia in the case of late stage Lyme disease
Pierre Bertholon +4 more
openalex +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
Not All Who Stagger Are Drunk: Ocular and Gait Abnormalities in a Young Adult. [PDF]
Knapp BJ +4 more
europepmc +1 more source
Absence seizures: Update on signaling mechanisms and networks
Abstract Absence seizures (AS) are a hallmark of genetic generalized epilepsies (GGE), characterized by brief episodes of impaired consciousness accompanied by electroencephalographic spike‐and‐wave discharges (SWDs). Traditionally attributed to cortico‐thalamo‐cortical (CTC) dysrhythmia, emerging evidence suggests a more intricate pathophysiological ...
Ozlem Akman, Filiz Onat
wiley +1 more source
Autoimmune cerebellopyramidal syndrome as a complex form of autoimmune cerebellar ataxia: a cohort study. [PDF]
Liu M, Ren H, Fan S, Zhang L, Guan H.
europepmc +1 more source
Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study
Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell +11 more
wiley +1 more source

